

Refine Search

Search Results -

Terms	Documents
photodynamic same liposome same peg	1

Database:

US Pre-Grant Publication Full-Text Database
US Patents Full-Text Database
US OCR Full-Text Database
EPO Abstracts Database
JPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Search:

L10

Search History

DATE: Tuesday, May 31, 2005 [Printable Copy](#) [Create Case](#)**Set Name Query**
side by side**Hit Count Set Name**
result set

<u>DB=USPT,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR</u>		
<u>L10</u> photodynamic same liposome same peg	1	<u>L10</u>
<u>L9</u> L8 and liposome	18	<u>L9</u>
<u>L8</u> \$porphyrin same peg	37	<u>L8</u>
<u>L7</u> porphyrinogen and 424/\$,ccls.	0	<u>L7</u>
<u>L6</u> porphyrinogen same liposome	0	<u>L6</u>
<u>L5</u> porphyrinogen	134	<u>L5</u>
<u>L4</u> L1 and peg	43	<u>L4</u>
<u>L3</u> L2 and peg	0	<u>L3</u>
<u>L2</u> \$chlorin same liposome	12	<u>L2</u>
<u>L1</u> \$chlorin	722	<u>L1</u>

END OF SEARCH HISTORY

[First Hit](#) [Fwd Refs](#)[Previous Doc](#) [Next Doc](#) [Go to Doc#](#)

End of Result Set

 [Generate Collection](#) [Print](#)

L10: Entry 1 of 1

File: USPT

Jan 4, 2000

DOCUMENT-IDENTIFIER: US 6010890 A

TITLE: Method for viral inactivation and compositions for use in same

Detailed Description Text (34):

With regard to the liposome composition, a specific feature that makes liposomes optimal for delivery of P_c4 has not been identified. Attaching PEG and producing "stealth" liposomes, an approach used to prevent removal of liposomes by the reticuloendothelial system (Allen, T. M. Trends Phar. Sci. 15:215-220 (1994), enhanced P_c4 binding to red cells (Table 2), and resulted in massive hemolysis. Incorporation of cholesterol in the liposomes resulted in even higher P_c4 binding to red cells. Liposomes composed of the synthetic phospholipids POPC and DOPS gave optimal results. Interestingly, although increasing the ratio of the charged moiety DOPS from 9:1 to 1:1 resulted in progressively reduced binding of P_c4 to red cells (Table 2), minimal hemolysis was obtained with a ratio of 4:1 (FIG. 4). The reasons for this apparent discrepancy are not known. One possibility could be greater lability of the more negatively charged liposomes to photodynamic degradation during light exposure. The P_c4 released would be available for binding to red cells. Greater lability could result from the presence of two oleic acid moieties in DOPS compared to one in POPC. Unsaturated fatty acids are more prone to oxidative damage than saturated ones.

[Previous Doc](#) [Next Doc](#) [Go to Doc#](#)

Refine Search

Search Results -

Terms	Documents
L1 and peg	43

Database:

US Pre-Grant Publication Full-Text Database
US Patents Full-Text Database
US OCR Full-Text Database
EPO Abstracts Database
JPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Search:

L4

Search History

DATE: Tuesday, May 31, 2005 [Printable Copy](#) [Create Case](#)

<u>Set Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
side by side			result set
DB=USPT,EPAB,JPAB,DWPI,TDBD;PLUR=YES;OP=OR			
<u>L4</u>	L1 and peg	43	<u>L4</u>
<u>L3</u>	L2 and peg	0	<u>L3</u>
<u>L2</u>	\$chlorin same liposome	12	<u>L2</u>
<u>L1</u>	\$chlorin	722	<u>L1</u>

END OF SEARCH HISTORY

Hit List

[Clear](#) [Generate Collection](#) [Print](#) [Fwd Refs](#) [Bkwd Refs](#)
[Generate GACS](#)

Search Results - Record(s) 1 through 12 of 12 returned.

1. Document ID: US 6800086 B2

L2: Entry 1 of 12

File: USPT

Oct 5, 2004

US-PAT-NO: 6800086

DOCUMENT-IDENTIFIER: US 6800086 B2

TITLE: Reduced fluence rate PDT

DATE-ISSUED: October 5, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Strong; H. Andrew	North Vancouver			CA

US-CL-CURRENT: 607/88; 128/898, 514/18

[Full](#) [Title](#) [Citation](#) [Front](#) [Review](#) [Classification](#) [Date](#) [Reference](#) [Claims](#) [KIMC](#) [Drawn D.](#)

2. Document ID: US 6703248 B1

L2: Entry 2 of 12

File: USPT

Mar 9, 2004

US-PAT-NO: 6703248

DOCUMENT-IDENTIFIER: US 6703248 B1

TITLE: Particles for diagnostic and therapeutic use

DATE-ISSUED: March 9, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Singh; Sharat	San Jose	CA		
Pease; John S.	Los Altos	CA		
Sadakian; Jacqueline	San Jose	CA		
Wagner; Daniel B.	Sunnyvale	CA		
Ullman; Edwin F.	Atherton	CA		

US-CL-CURRENT: 436/518; 422/82.05, 422/82.07, 422/82.08, 436/164, 436/166, 436/172,
436/520, 436/523, 436/524, 436/528, 436/533, 436/534, 436/535, 436/546, 436/8

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMNC	Drawn D
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	---------

3. Document ID: US 6022526 A

L2: Entry 3 of 12

File: USPT

Feb 8, 2000

US-PAT-NO: 6022526

DOCUMENT-IDENTIFIER: US 6022526 A

** See image for Certificate of Correction **

TITLE: Use of texaphyrins in detection of melanin and melanin metabolites diagnostic of melanotic melanoma

DATE-ISSUED: February 8, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Woodburn; Kathryn W.	Sunnyvale	CA		
Young; Stuart W.	Portola Valley	CA		

US-CL-CURRENT: 424/9.61; 424/1.11, 424/1.65, 424/9.1, 424/9.3, 424/9.6, 435/7.1,
435/7.23, 436/518, 436/58, 436/64

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMNC	Drawn D
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	---------

4. Document ID: US 5225433 A

L2: Entry 4 of 12

File: USPT

Jul 6, 1993

US-PAT-NO: 5225433

DOCUMENT-IDENTIFIER: US 5225433 A

** See image for Certificate of Correction **

TITLE: Treatment of tumors using chlorins

DATE-ISSUED: July 6, 1993

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Dougherty; Thomas J.	Grand Island	NY		
Potter; William R.	Grand Island	NY		
Weishaup; Kenneth R.	Sloan	NY		

US-CL-CURRENT: 514/410; 540/145

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMNC	Drawn D
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	---------

5. Document ID: US 5145863 A

L2: Entry 5 of 12

File: USPT

Sep 8, 1992

US-PAT-NO: 5145863

DOCUMENT-IDENTIFIER: US 5145863 A

**** See image for Certificate of Correction ****

TITLE: Method to destroy or impair target cells

DATE-ISSUED: September 8, 1992

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Dougherty; Thomas J.	Grand Island	NY		
Potter; William R.	Grand Island	NY		
Weishaupt; Kenneth R.	Sloan	NY		

US-CL-CURRENT: 514/410; 128/898, 540/145, 604/21, 604/500, 607/901[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | | | | [Claims](#) | [KWC](#) | [Drawn D](#)

 6. Document ID: US 5041078 A

L2: Entry 6 of 12

File: USPT

Aug 20, 1991

US-PAT-NO: 5041078

DOCUMENT-IDENTIFIER: US 5041078 A

**** See image for Certificate of Correction ****

TITLE: Photodynamic viral deactivation with sapphyrins

DATE-ISSUED: August 20, 1991

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Matthews; J. Lester	Dallas	TX		
Judy; Millard M.	Dallas	TX		
Newman; Joseph T.	Dallas	TX		
Sogandares-Bernal; Frank	Dallas	TX		
Sessler; Jonathan L.	Austin	TX		
Harriman; Anthony	Austin	TX		
Maiya; Bhaskar G.	Hyderabad			IN

US-CL-CURRENT: 604/6.08; 540/145[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | | | | [Claims](#) | [KWC](#) | [Drawn D](#)

 7. Document ID: US 5028621 A

L2: Entry 7 of 12

File: USPT

Jul 2, 1991

US-PAT-NO: 5028621
DOCUMENT-IDENTIFIER: US 5028621 A

TITLE: Drugs comprising porphyrins

DATE-ISSUED: July 2, 1991

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Dougherty; Thomas J.	Grand Island	NY		
Potter; William R.	Grand Island	NY		
Weishaupt; Kenneth R.	Sloan	NY		

US-CL-CURRENT: 514/410; 540/145

Full | Title | Citation | Front | Review | Classification | Date | Reference | | | | Claims | KJC | Drawn D

8. Document ID: US 5015463 A

L2: Entry 8 of 12

File: USPT

May 14, 1991

US-PAT-NO: 5015463
DOCUMENT-IDENTIFIER: US 5015463 A

TITLE: Method to diagnose the presence or absence of tumor tissue

DATE-ISSUED: May 14, 1991

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Dougherty; Thomas J.	Grand Island	NY		
Potter; William R.	Grand Island	NY		
Weishaupt; Kenneth R.	Sloan	NY		

US-CL-CURRENT: 424/9.61; 514/410, 540/145

Full | Title | Citation | Front | Review | Classification | Date | Reference | | | | Claims | KJC | Drawn D

9. Document ID: US 4932934 A

L2: Entry 9 of 12

File: USPT

Jun 12, 1990

US-PAT-NO: 4932934
DOCUMENT-IDENTIFIER: US 4932934 A

TITLE: Methods for treatment of tumors

DATE-ISSUED: June 12, 1990

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Dougherty; Thomas J.	Grand Island	NY		
Potter; William R.	Grand Island	NY		
Weishaupt; Kenneth R.	Sloan	NY		

US-CL-CURRENT: 604/21; 128/898, 514/410, 540/145, 604/506, 607/89, 607/901

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWMC | Drawn D:

10. Document ID: US 4889129 A

L2: Entry 10 of 12

File: USPT

Dec 26, 1989

US-PAT-NO: 4889129

DOCUMENT-IDENTIFIER: US 4889129 A

TITLE: Apparatus for treatment of tumors

DATE-ISSUED: December 26, 1989

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Dougherty; Thomas J.	Grand Island	NY		
Potter; William R.	Grand Island	NY		
Weishaupt; Kenneth R.	Sloan	NY		

US-CL-CURRENT: 600/473; 600/476, 606/16, 606/17, 606/4

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWMC | Drawn D:

11. Document ID: US 4866168 A

L2: Entry 11 of 12

File: USPT

Sep 12, 1989

US-PAT-NO: 4866168

DOCUMENT-IDENTIFIER: US 4866168 A

TITLE: Hematoporphyrin derivatives and process of preparing

DATE-ISSUED: September 12, 1989

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Dougherty; Thomas J.	Grand Island	NY		
Potter; William R.	Grand Island	NY		
Weishaupt; Kenneth R.	Sloan	NY		

US-CL-CURRENT: 540/145

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMC	Draw. D.
------	-------	----------	-------	--------	----------------	------	-----------	--------	-----	----------

□ 12. Document ID: US 4649151 A

L2: Entry 12 of 12

File: USPT

Mar 10, 1987

US-PAT-NO: 4649151

DOCUMENT-IDENTIFIER: US 4649151 A

TITLE: Drugs comprising porphyrins

DATE-ISSUED: March 10, 1987

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Dougherty; Thomas J.	Grand Island	NY		
Potter; William R.	Grand Island	NY		
Weishaupt; Kenneth R.	Sloan	NY		

US-CL-CURRENT: 514/410; 540/145

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMC	Draw. D.
------	-------	----------	-------	--------	----------------	------	-----------	--------	-----	----------

Clear**Generate Collection****Print****Fwd Refs****Bkwd Refs****Generate GACS**

Terms	Documents
\$chlorin same liposome	12

Display Format: [-] **Change Format**[Previous Page](#)[Next Page](#)[Go to Doc#](#)

[First Hit](#) [Fwd Refs](#)[Previous Doc](#) [Next Doc](#) [Go to Doc#](#) [Generate Collection](#) [Print](#)

L4: Entry 42 of 43

File: USPT

Feb 14, 1995

DOCUMENT-IDENTIFIER: US 5389378 A

TITLE: Benzoporphyrin vesicles and their use in photodynamic therapy

Brief Summary Text (11):

Benzoporphyrin derivative (BPD) represents a second generation of photosensitizers which are superior to HPD. BDP is a chlorin-like porphyrin composed of four structural analogues following synthesis. All four analogues have an identical reduced tetrapyrrol porphyrin ring. Each analogue differs only by the position of a cyclohexadiene ring which may be fused either at ring A or ring B of the porphyrin (A or B analogues) and the presence of either two acid groups (diacids) or one acid and one ester group (monoacids) at rings C and D of the porphyrin (See FIG. 1). All four analogues are hydrophobic, absorb red light at about 700 nm and efficiently produce singlet oxygen. Despite the sensitivity of all four molecules, they differ in their light activated cytotoxicity in vitro and in vivo.

Detailed Description Text (3):

Benzoporphyrin derivative (BPD) is a chlorin-like photosensitizer and is represented by four analogues, two of which are diacids and two of which are monoacids. All four analogues have an identical reduced tetrapyrrol porphyrin ring. Each analogue differs only by the position of a cyclohexadiene ring which may be fused either at ring A or ring B of the porphyrin (ring A or B analogues) and the presence of either one or two acid groups (monoacids and diacids, respectively) at rings C and D of the porphyrin moiety (See FIG. 1). All four analogues are hydrophobic, absorb red light at about 700 nm and efficiently produce singlet oxygen. Despite the sensitivity of all four molecules, they differ in their light activated cytotoxicity in vitro and in vivo.

Detailed Description Text (13):

In a number of embodiments of the present invention, a steroidal component may be added to the liposome. For purposes of the present invention any component including the above-described phospholipids which may be used to produce a liposome either alone or in combination with a phospholipid is termed a liposome producing lipid. In certain embodiments of the present invention, the amount of liposome forming lipid may range from about 10% to about 100% by weight of the liposome and in preferred embodiments of the present invention, the liposome producing lipid comprises at least about 50 mole percent of the total weight of the lipids of the liposome. Any of the above-mentioned phospholipids may be used in combination with at least one additional component selected from the group consisting of cholesterol, cholestanol, coprostanol or cholestane. In addition, polyethylene glycol derivatives of cholesterol (PEG-cholesterols), as well as organic acid derivatives of sterols, for example cholesterol hemisuccinate (CHS) may also be used alone or preferably in combination with any of the above-mentioned phospholipids. Organic acid derivatives of alphatocopherol hemisuccinate, (THS) may also be used. CHS- and THS-containing liposomes and their tris salt forms may generally be prepared by any method known in the art for preparing liposomes containing sterols, so long as the resultant phospholipid-sterol mixture yields stable liposomes. In particular, see the procedures of Janoff, et al., U.S. Pat. No. 4,721,612, issued Jan. 26, 1988, entitled "Steroidal Liposomes" and Janoff, et al., U.S. Pat. No. 4,861,580, issued Aug. 29, 1989, PCT Publication No. 87/02219, published Apr. 23, 1987, entitled "Alpha Tocopherol-Based Vehicles", relevant

portions of which are incorporated by reference herein. In certain embodiments containing cholesterol, the cholesterol is utilized in combination with EPC in a molar ratio of cholesterol to EPC of about 45:55.

[Previous Doc](#)[Next Doc](#)[Go to Doc#](#)